Key Takeaways Pfizer is licensing global rights to YP05002, an oral GLP-1 agonist now in phase I.YaoPharma will finish phase I before Pfizer advances YP05002 and pairs it with PF-07976016.The deal follows Pfizer's $10B Metsera buyout as it works to regain ground in obesity.Pfizer (PFE) announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) from YaoPharma, a subsidiary of China’s leading drugmaker, ...